Relationship of Ki67, TP53, MDM-2 and BCL-2 expressions with WHO 1973 and WHO/ISUP grades, tumor category and overall patient survival in urothelial tumors of the bladder

Pathology Research and Practice

Volumn 204, Issue 10, 2008, Pages 707-717

  Işik Gönül, Ipek ^a   Akyürek, Nalan ^a   Dursun, Ayşe ^a   Küpeli, Bora ^a  

^a GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

Grading; Oncogenes; Proliferative activity; Urothelial carcinoma

Indexed keywords

KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P53;

ACCURACY; ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER CLASSIFICATION; CANCER GRADING; CANCER RECURRENCE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENCE RISK; TRANSURETHRAL RESECTION; UROTHELIUM; WORLD HEALTH ORGANIZATION;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MDM2; TERMINOLOGY AS TOPIC; TIME FACTORS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS; UROTHELIUM; WORLD HEALTH ORGANIZATION;

EID: 52049101783     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2008.03.011     Document Type: Article

References (48)

1. Busch C., and Algaba F. The WHO/ISUP 1998 and WHO 1999 systems for malignancy grading of bladder cancer. Scientific foundation and translation to one another and previous systems. Virchows Arch. 441 (2002) 105-108
2. Cina S.J., Lancaster-Weiss K.J., Lecksell K., and Epstein J.I. Correlation of Ki-67 and TP53 with the new World Health Organization/International Society of Urological Pathology classification system for urothelial neoplasia. Arch. Pathol. Lab. Med. 125 (2001) 646-651
3. Compérat E., Camparo P., Haus R., Chartier-Kastler E., Bart S., Delcourt A., Houlgatte A., François R., Capron F., and Vieillefond A. Immunohistochemical expression of p63, p53 and MIB-1 in urinary bladder carcinoma. A tissue microarray study of 158 cases. Virchows Arch. 448 (2006) 319-324
4. Dalesio O., Schulman C.C., Sylvester R., De Pauw M., Robinson M., Denis L., Smith P., and Viggiano G. Prognostic factors in superficial bladder tumors. A study of the European Organization for Research on Treatment of Cancer: Genitourinary Tract Cancer Cooperative Group. J. Urol. 129 (1983) 730-733
5. Epstein J.I., Amin M.B., Reuter V.R., and Mostofi F.K. The bladder consensus conference committee The World Health Organization/International Society of Urological Pathology Consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. The Bladder Consensus conference committee. Am. J. Surg. Pathol. 22 (1998) 1435-1448
6. Friedrich M.G., Riethdorf S., and Erbersdobler A. Relevance of p53 gene alterations for tumor recurrence in patients with superficial transitional cell carcinoma of the bladder. Eur. Urol. 39 (2001) 159-166
7. Glick S.H., Howell L.P., and White R.W. Relationship of TP53 and BCL-2 to prognosis in muscle invasive transitional cell carcinoma of the bladder. J. Urol. 155 (1996) 1754-1757
8. Gontero P., Casetta G., Zitella A., Ballario R., Pacchioni D., Magnani C., Muir G.H., and Tizzani A. Evaluation of TP53 protein over expression, Ki67 proliferative activity and mitotic index as markers of tumor recurrence in superficial transitional cell carcinoma of the bladder. Eur. Urol. 38 (2000) 287-296
9. Gonzalez-Campora R., Davalos-Casanova G., Beato-Moreno A., Luque R.J., Alvarez-Kindelan J., Requena M.J., Montironi R., and Lopez-Beltran A. Apoptotic and proliferation indexes in primary superficial bladder tumors. Cancer Lett. 242 (2006) 266-272
10. Gonzalez-Campora R., Davalos-Casanova G., Beato-Moreno A., Garcia-Escudero A., Megia M.J.P., Montironi R., and Lopez-Beltran A. BCL-2, TP53 and BAX protein expression in superficial urothelial bladder carcinoma. Cancer Lett. 250 (2007) 292-299
11. Holmang S., Hedelin H., Anderstrom C., Holmberg E., Busch C., and Johansson S.L. Recurrence and progression in low grade papillary urothelial tumors. J. Urol. 162 (1999) 702-707
12. Holmang S., Andius P., Hedelin H., Wester K., Busch C., and Johansson S.L. Stage progression in Ta papillary urothelial tumors: Relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy. J. Urol. 165 (2001) 1124-1130
13. Jimenez R.E., Gheiler E., Oskanian P., Tiguert R., Sakr W., Wood Jr. D.P., Pontes J.E., and Grignon D.J. Grading the invasive component of urothelial carcinoma of the bladder and its relationship with progression-free survival. Am. J. Surg. Pathol. 24 (2000) 980-987
14. Jordan A.M., Weingarten J., and Murphy W.M. Transitional cell neoplasms of the urinary bladder. Can biologic potential be predicted from histological grading?. Cancer 60 (1987) 2766-2774
15. Kaubisch S., Lum B.L., Reese J., Freiha F., and Torti F.M. Stage T1 bladder cancer: grade is the primary determinant for risk of muscle invasion. J. Urol. 146 (1991) 28-31
16. Ki{dotless}li{dotless}cli{dotless}-Camur N., Kilicarslan I., Gulluoglu M.G., Esen T., and Uysal V. Impact of p53 and Ki67 in predicting recurrence and progression of superficial (pTa and pT1) urothelial cell carcinomas of urinary bladder. Pathol. Int. 52 (2002) 463-469
17. Kirsh E.J., Baunoch D.A., and Stadler W.M. Expression of BCL-2 and bcl-x in bladder cancer. J. Urol. 159 (1998) 1348-1351
18. Korkolopoulou P., Christodoulou P., Kapralos P., Exarchakos M., Bisbiroula A., Hadjiyannakis M., Georgountzos C., and Thomas-Tsagli E. The role of TP53, MDM-2 and c-erb B2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer. Pathol. Res. Pract. 193 (1997) 767-775
19. Kroft S.H., and Oyasu R. Biology of disease. Urinary bladder cancer: mechanisms of development and progression. Lab. Invest. 71 (1994) 158-174
20. Larsson P., Wijkstrom H., Thorstenson A., Adolfsson J., Norming U., Wiklund P., Onelov E., and Steineck G. A population based study of 538 patients with newly detected urinary bladder neoplasms followed during 5 years. Scand. J. Urol. Nephrol. 37 (2003) 195-201
21. Lipponen P.K., Aaltomaa S., and Eskelinen M. Expression of the apoptosis suppressing BCL-2 protein in transitional cell bladder tumors. Histopathology 28 (1996) 135-140
22. Liukkonen T., Rajala P., Raitanen M., Rintala E., Kaasinen E., and Lipponen P. Prognostic value of MIB-1 score, TP53, EGFr, mitotic index and papillary status in primary superficial (stage pTa/pT1) bladder cancer: a prospective comparative study. Eur. Urol. 36 (1999) 393-400
23. Llopis J., Alcaraz A., Ribal M.J., Sole M., Ventura P.J., Barranco M.A., Rodriguez A., Corral J.M., and Carretero P. TP53 expression predicts progression and poor survival in T1 bladder tumors. Eur. Urol. 37 (2000) 644-653
24. Malmstrom P.U., Busch C., and Norlen B.J. Recurrence, progression and survival in bladder cancer. A retrospective analysis of 232 patients with greater than or equal to 5-year follow-up. Scand. J. Urol. 21 (1987) 185-195
25. Mazerolles C., Rishmann P., Chopin D., Popov Z., Malavaud B., Selves J., Neulat-Duga I., Bellot J., and Delsol G. Usefulness of MIB-1 monoclonal antibody in assessing the proliferative index in human bladder carcinoma: comparison with Ki67 antibody. Histopathology 25 (1994) 563-568
26. Mhawech P., Greloz V., Oppikofer C., Szalay-Quinodoz I., and Herrmann F. Expression of cell cycle proteins in T1a and T1b urothelial bladder carcinoma and their value in predicting tumor progression. Cancer 100 (2004) 2367-2374
27. Montironi R., Mazzucchelli R., Colanzi P., Streccioni M., Scarpelli M., Thompson D., and Bartels P.H. Improving interobserver agreement and certainty level in diagnosing and grading papillary urothelial neoplasms. Usefulness of a Bayesian belief network. Eur. Urol. 41 (2002) 449-457
28. F.K. Mostofi, L.H. Sobin, H. Torloni, Histologic typing of urinary bladder tumors: international histological classification of tumors. WHO (10), Geneva, 1973.
29. Mulder A.H., Van Hootegem J.C., Sylvester R., ten Kate F.J., Kurth K.H., Ooms E.C., and Van der Kwast T.H. Prognostic factors in bladder carcinoma: histological parameters and expression of a cell cycle related nuclear antigen (Ki67). J. Pathol. 166 (1992) 37-43
30. Oosterhuis J.W., Schapers R.F., Janssen-Heijnen M.L., Smeets A.W., and Pauwels R.P. MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder. Clinical significance and comparison with other prognostic factors. Cancer 88 (2000) 2598-2605
31. Pauwels R.P., Schapers R.F., Smeets A.W., Debruyne F.M., and Geraedts J.P. Grading in superficial bladder cancer. Morphological criteria. Br. J. Urol. 61 (1988) 129-134
32. Quintero A., Alvarez-Kindelan J., Luque R.J., Gonzalez-Campora R., Requena M.J., Montironi R., and Lopez-Beltran A. Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder. J. Clin. Pathol. 59 (2006) 83-88
33. Reuter V.E. Bladder - risk and prognostic factors - a pathologist's perspective. Urol. Clin. North Am. 26 (1999) 481-492
34. Reuter V.R., Epstein J.I., Amin M.B., Mostofi F.K., and The Bladder Consensus Conference Committee. A newly illustrated synopsis of the World Health Organization/International Society of Urological Pathology (WHO/ISUP) Consensus Classification of urothelial (transitional cell) neoplasms of the urinary bladder. The Bladder Consensus Committee. J. Urol. Pathol. 11 (1999) 1-27
35. Rodriguez Alonso A., Pita Fernandez S., Gonzalez-Carrero J., and Nogueira March J.L. Multivariate analysis of recurrence and progression in stage T1 transitional-cell carcinoma of the bladder. Prognostic value of p53 and Ki67. Actas Urol. Esp. 27 (2003) 132-141
36. Santos L.L., Amaro T., Pereira S.A., Lameiras C.R., Lopes P., Bento M.J., Oliveira J., Criadok B., and Lopes C.S. Expression of cell-cycle regulatory proteins and their prognostic value in superficial low-grade urothelial cell carcinoma of the bladder. EJSO 29 (2003) 74-80
37. Sauter G., Algaba F., Amin M.B., Busch C., Cheville J., Gasser T., Grignon D., Hofstaedter F., Lopez-Beltran A., and Epstein J.I. Noninvasive urothelial neoplasias. In: Eble J.N., Epstein J.I., and Sesterhenn I. (Eds). World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs (2004), IARCC Press, Lyon 110-123
38. Shariat S.F., Kim J., Raptidis G., Ayala G., and Lerner S. Association of p63 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. Urology 61 (2003) 1140-1145
39. Shiina H., Igawa M., Shigeno K., Yamasaki Y., Urakami S., Yoneda T., Wada Y., Honda S., and Nagasaki M. Clinical significance of mdm-2 and TP53 expression in bladder cancer. Oncology 56 (1999) 239-247
40. Torti F.M., and Lum B.L. Superficial bladder cancer: risk of recurrence and potential role for interferon therapy. Cancer 59 (1987) 613-616
41. Tuna B., Yorukoglu K., Tuzel E., Guray M., Mungan U., and Kirkali Z. Expression of p53 and mdm-2 and their significance in recurrence of superficial bladder cancer. Pathol. Res. Pract. 199 (2003) 323-328
42. Vatne V., Maartman-Moe H., and Hoestmark J. The prognostic value of TP53 in superficially infiltrasting transitional cell carcinoma. Scand. J. Urol. Nephrol. 29 (1995) 491-495
43. Vet J.A., Bringuier P.P., Poddighe P.J., Karthaus H.F., Debruyne F.M., and Schalken J.A. TP53 mutations have no additional prognostic value over stage in bladder cancer. Br. J. Cancer 70 (1994) 496-500
44. Vogelstein B., and Kinzler K.W. TP53 function and dysfunction. Cell 70 (1992) 523-526
45. Vollmer R.T., Humphrey P.A., Swanson P.E., Wick M.R., and Hudson M.L. Invasion of the bladder by transitional cell carcinoma. Its relation to histological grade and expression of TP53, MIB-1, c-erb B-2, epidermal growth factor receptor and BCL-2. Cancer 82 (1998) 715-723
46. Wu T.T., Chen J.H., Lee Y.H., and Huang J.K. The role of BCL-2, TP53 and Ki67 index in predicting tumor recurrence for low grade superficial transitional cell bladder carcinoma. J. Urol. 163 (2000) 758-760
47. Yorukoglu K., Tuna B., Dikicioglu E., Duzcan E., Isisag A., Sen S., Mungan U., and Kirkali Z. Reproducibility of the 1998 World Health Organization/International Society of Urologic Pathology classification of papillary urothelial neoplasms of the urinary bladder. Virchows Arch. 443 (2003) 734-740
48. Yurakh A.O., Ramos D., Calabuig-Fariñas S., López-Guerrero J.A., Rubio J., Solsona E., Romanenko A.M., Vozianov A.F., Pellin A., and Llombart-Bosch A. Molecular and immunohistochemical analysis of the prognostic value of cell-cycle regulators in urothelial neoplasms of the bladder. European Urology 50 (2006) 506-515